CYTK
Cytokinetics, IncorporatedNASDAQHealthcare$66.73+0.18%ClosedMarket Cap: $8.22B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-12.34
P/S
93.35
EV/EBITDA
-12.29
DCF Value
$-55.55
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-22.3%
Operating Margin
-695.4%
Net Margin
-891.6%
ROE
172.9%
ROA
-55.1%
ROIC
-47.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $17.8M | 83.9% | $-178.4M | $-183.0M | $-1.50 | — |
| FY 2025 | $88.0M | 88.5% | $-612.3M | $-785.0M | $-6.54 | — |
| Q3 2025 | $1.9M | -38.4% | $-166.8M | $-306.2M | $-2.55 | — |
| Q2 2025 | $66.8M | 96.6% | $-111.5M | $-134.4M | $-1.12 | — |
| Q1 2025 | $1.6M | -6223.1% | $-155.6M | $-161.4M | $-1.36 | — |
| Q4 2024 | $16.9M | -453.1% | $-139.0M | $-150.0M | $-1.27 | — |
| FY 2024 | $18.5M | -1737.2% | $-536.2M | $-589.5M | $-5.26 | — |
| Q3 2024 | $463.0K | -18174.7% | $-140.8M | $-160.5M | $-1.36 | — |
| Q2 2024 | $249.0K | -31866.7% | $-130.2M | $-143.3M | $-1.31 | — |
| Q1 2024 | $835.0K | -9668.9% | $-126.2M | $-135.6M | $-1.33 | — |
| Q4 2023 | $1.7M | -4982.3% | $-127.4M | $-136.9M | $-1.38 | — |
| FY 2023 | $7.5M | -4284.1% | $-496.2M | $-526.2M | $-5.45 | — |